BDXBECTON DICKINSON & CO

NYSE bd.com


$ 228.91 $ -0.19 (-0.08 %)    

Monday, 15-Jul-2024 10:18:59 EDT
QQQ $ 497.61 $ 0.88 (0.18 %)
DIA $ 402.19 $ -0.41 (-0.1 %)
SPY $ 562.53 $ 0.35 (0.06 %)
TLT $ 92.91 $ -0.05 (-0.05 %)
GLD $ 223.93 $ 0.51 (0.23 %)
$ 229.11
$ 229.10
$ 0.00 x 0
$ 0.00 x 0
$ 228.29 - $ 230.77
$ 218.75 - $ 282.90
2,220,555
na
66.21B
$ 0.45
$ 50.24
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-01-2024 12-31-2023 10-Q
3 11-21-2023 09-30-2023 10-K
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-02-2023 12-31-2022 10-Q
7 11-22-2022 09-30-2022 10-K
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-03-2022 12-31-2021 10-Q
11 11-24-2021 09-30-2021 10-K
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-04-2021 12-31-2020 10-Q
15 11-25-2020 09-30-2020 10-K
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-06-2020 12-31-2019 10-Q
19 11-27-2019 09-30-2019 10-K
20 08-06-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-05-2019 12-31-2018 10-Q
23 11-21-2018 09-30-2018 10-K
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-06-2018 12-31-2017 10-Q
27 11-22-2017 09-30-2017 10-K
28 08-03-2017 06-30-2017 10-Q
29 05-02-2017 03-31-2017 10-Q
30 02-02-2017 12-31-2016 10-Q
31 11-23-2016 09-30-2016 10-K
32 08-04-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-05-2016 12-31-2015 10-Q
35 11-25-2015 09-30-2015 10-K
36 08-06-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-06-2015 12-31-2014 10-Q
39 11-26-2014 09-30-2014 10-K
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 unitedhealth-edwards-lifesciences-first-citizens-bank-and-more-cnbcs-final-trades

UnitedHealth Group was declared a "solid" healthcare company on CNBC. Cantor Fitzgerald analyst Sarah James maintains a...

 citigroup-maintains-neutral-on-becton-dickinson-lowers-price-target-to-255

Citigroup analyst Joanna Wiensch maintains Becton Dickinson (NYSE:BDX) with a Neutral and lowers the price target from $260 ...

 fda-says--aware-that-us-is-experiencing-interruptions-in-the-supply-of-bd-bactec-blood-culture-media-bottles-because-of-recent-supplier-issues

- Reuters

 becton-dickinson-says-it-has-surpassed-its-scope-1-and-2-science-based-greenhouse-gas-ghg-emissions-reduction-targets-for-fy-2023-by-5-percentage-points

 This furthers the company's progress toward its goal to reach net zero GHG emissions across its value chain by FY 2050

 evercore-isi-group-maintains-outperform-on-becton-dickinson-lowers-price-target-to-285

Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:BDX) with a Outperform and lowers the price target f...

 bd-bolsters-portfolio-with-42b-cash-deal-for-edwards-lifesciences-critical-care-group-details

BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash....

Core News & Articles

Critical Care has approximately 4,500 employees with most based in Irvine, California. In 2023, the business generated more tha...

Core News & Articles

With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the aft...

 goldman-sachs-initiates-coverage-on-becton-dickinson-with-buy-rating-announces-price-target-of-274

Goldman Sachs analyst David Roman initiates coverage on Becton Dickinson (NYSE:BDX) with a Buy rating and announces Price Ta...

 bidens-new-tariffs-on-chinese-imports-are-a-clear-giveaway-to-these-two-tesla-rivals-jim-cramer-says-i-like-this-policy

Jim Cramer has highlighted the potential benefits for U.S. automakers, particularly Ford and General Motors, following the Bide...

Core News & Articles

- Reuters

 barclays-maintains-overweight-on-becton-dickinson-raises-price-target-to-312

Barclays analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Overweight and raises the price target from $305 ...

 becton--dickinson-is-well-on-its-way-to-achieving-2025-commitments-analyst-optimistic-on-outlook

BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance...

 becton-dickinson-q2-2024-adj-eps-317-beats-297-estimate-sales-504b-inline

Becton, Dickinson (NYSE:BDX) reported quarterly earnings of $3.17 per share which beat the analyst consensus estimate of $2.97 ...